Relapsed / Refractory CLL
Showing 1 - 25 of >10,000
Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma Trial in Chicago, Rochester, Cleveland (Venetoclax, Umbralisib, Ublituximab)
Terminated
- Chronic Lymphocytic Leukemia
- Non-Hodgkin Lymphoma
- Venetoclax
- +3 more
-
Chicago, Illinois
- +2 more
Aug 19, 2022
Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small
Recruiting
- Relapsed or Refractory CD19+ B-cell Lymphoma
- +2 more
- TBI-2001
- +2 more
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Jul 26, 2023
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial (CB-012)
Not yet recruiting
- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia Refractory
- (no location specified)
Nov 9, 2023
Chronic Lymphocytic Leukemia, Richter Syndrome Trial in United States (Duvelisib, Venetoclax)
Recruiting
- Chronic Lymphocytic Leukemia
- Richter Syndrome
-
Miami, Florida
- +6 more
Jan 6, 2023
AML, Adult Trial in Hangzhou (CLL1 CAR-NK cell injection)
Recruiting
- AML, Adult
- CLL1 CAR-NK cell injection
-
Hangzhou, Zhejiang, ChinaClinical research ethics committee of the first affiliated hospi
Aug 30, 2023
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial run by the (Acalabrutinib (Arm A), Acalabrutinib (Arm B))
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Acalabrutinib (Arm A)
- Acalabrutinib (Arm B)
-
Bethesda, MarylandResearch Site
Jan 3, 2023
Acute Myeloid Leukemia Trial in Beijing, Tianjin (LCAR-AMDR Cells Product)
Recruiting
- Acute Myeloid Leukemia
- LCAR-AMDR Cells Product
-
Beijing, Beijing, China
- +1 more
Jan 28, 2023
Chronic Lymphocytic Leukemia(CLL), Small Lymphocytic Lymphoma Trial in Hackensack (Revlimid, Azacitidine)
Terminated
- Chronic Lymphocytic Leukemia(CLL)
- Small Lymphocytic Lymphoma
-
Hackensack, New JerseyHackensack University Medical Center
Jun 24, 2022
Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma Trial (Nemtabrutinib, Venetoclax,
Not yet recruiting
- Leukemia, Lymphocytic, Chronic, B-Cell
- +5 more
- Nemtabrutinib
- +2 more
- (no location specified)
Jul 21, 2023
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia Trial in Boston (Acalabrutinib,
Active, not recruiting
- Chronic Lymphocytic Leukemia
- +3 more
- Acalabrutinib
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Dec 19, 2022
Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Prolymphocytic Leukemia Trial
Active, not recruiting
- Contiguous Stage II Small Lymphocytic Lymphoma
- +11 more
- MOR00208
- +2 more
-
Columbus, OhioThe Ohio State University Comprehensive Cancer Center
Feb 24, 2022
Follicular B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma Recurrent, Mantle Cell Lymphoma Refractory Trial in Orange,
Recruiting
- Follicular B-cell Non-Hodgkin's Lymphoma
- +7 more
- MB-106
-
Orange, California
- +3 more
Nov 1, 2022
Acute Myeloid Leukemia Trial in Kunming (CLL1 and CD38 dual-target CAR-T injection)
Recruiting
- Acute Myeloid Leukemia
- CLL1 and CD38 dual-target CAR-T injection
-
Kunming, Yunnan, China920th Hospital of Joint LogisticsSupport Force of People's Liber
Oct 26, 2023
Chronic Lymphocytic Leukemia, CLL, Relapsed CLL Trial (Dose combination 1-1, dose combination 1-2, Dose combination 1-3)
Withdrawn
- Chronic Lymphocytic Leukemia
- +8 more
- Dose combination 1-1
- +5 more
- (no location specified)
Nov 1, 2021
Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial in Beijing
Recruiting
- Relapsed or Refractory B-cell Lymphoma
- +6 more
-
Beijing, ChinaBeijing Cancer Hospital
Feb 6, 2023
Chronic Lymphoid Leukemia Trial in Germany (Bendamustine, Obinutuzumab, Acalabrutinib)
Active, not recruiting
- Chronic Lymphoid Leukemia
- Bendamustine
- +3 more
-
Dresden, Germany
- +16 more
Nov 8, 2022
Chronic Lymphocytic Leukemia Trial in Lebanon (BNC105P, Ibrutinib)
Completed
- Chronic Lymphocytic Leukemia
- BNC105P
- Ibrutinib
-
Lebanon, New HampshireDartmouth-Hitchcock Medical Center
Jan 3, 2023
B-cell NHL, CLL Trial (CARCIK-CD19)
Not yet recruiting
- B-cell NHL
- CLL
- CARCIK-CD19
- (no location specified)
May 19, 2023
AML Trial in Hangzhou (CLL1 CAR-T)
Not yet recruiting
- AML
- CLL1 CAR-T
-
Hangzhou, ChinaThe First Affiliated Hospital, Zhejiang University
Jul 17, 2022
AML Trial in Hangzhou (CLL1+CD33 CAR-T)
Not yet recruiting
- AML
- CLL1+CD33 CAR-T
-
Hangzhou, ChinaMingming Zhang Zhang
Jul 19, 2022
Chronic Lymphocytic Leukemia (CLL) Trial in Boston (Ibrutinib, Copanlisib, Acalabrutinib)
Recruiting
- Chronic Lymphocytic Leukemia (CLL)
- Ibrutinib
- +2 more
-
Boston, MassachusettsDana-Farber Cancer Institute
May 13, 2022
Chronic Lymphocytic Leukemia Trial in Washington, Hackensack (Venetoclax, Rituximab, Rituximab/Hyaluronidase Human)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Venetoclax
- +2 more
-
Washington, District of Columbia
- +1 more
Mar 14, 2022
B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Charleston (Cyclophosphamide injection, Fludarabine
Not yet recruiting
- B-cell Non Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia
- Cyclophosphamide injection
- +2 more
-
Charleston, South CarolinaHollings Cancer Center at Medical University of South Carolina
Jan 18, 2023